Concomitant Aficamten and Disopyramide in Symptomatic Obstructive Hypertrophic Cardiomyopathy
In this cohort of patients with symptomatic oHCM with persistent LVOT obstruction, combination therapy with aficamten and disopyramide was safe and well tolerated but did not enhance clinical efficacy vs aficamten alone. For such oHCM patients, aficamten treatment may be considered with an option to discontinue disopyramide. (Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM [REDWOOD-HCM]; NCT04219826) (Aficamten vs Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy [SEQUOIA-HCM]; NCT05186818) (Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM [FOREST-HCM]; NCT04848506).
Authors
- Theodore P. Abraham (ORCID: https://orcid.org/0000-0001-8966-6906)
- Roberto Barriales‐Villa (ORCID: https://orcid.org/0000-0002-6721-3487)
- Perry Elliott (ORCID: https://orcid.org/0000-0003-3383-3984)
- Artur Oręziak (ORCID: https://orcid.org/0000-0003-3318-3643)
- Stephen B. Heitner (ORCID: https://orcid.org/0000-0003-2189-1474)
- Daniele Massera (ORCID: https://orcid.org/0000-0002-9499-6456)
- Sara Saberi (ORCID: https://orcid.org/0000-0003-4473-6725)
- Ozlem Bilen (ORCID: https://orcid.org/0000-0002-3078-5262)
- Jenny Wei (ORCID: https://orcid.org/0009-0000-5828-5705)
- ANJALI TIKU OWENS (ORCID: https://orcid.org/0000-0002-9669-8495)
- Caroline Coats (ORCID: https://orcid.org/0000-0002-3208-470X)
- Albree Tower‐Rader
- Mark V. Sherrid (ORCID: https://orcid.org/0000-0003-4972-7780)
- Scott David Solomon (ORCID: https://orcid.org/0000-0003-3698-9597)
- Chiara Melloni
- Pablo García‐Pavía (ORCID: https://orcid.org/0000-0002-5470-2257)
- Daniel Jacoby (ORCID: https://orcid.org/0000-0002-9182-275X)
- Iacopo Olivotto
- Ahmad Masri (ORCID: https://orcid.org/0000-0002-6390-6526)
- Michael E. Nassif (ORCID: https://orcid.org/0000-0002-1232-7604)
- Martin S. Maron
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Emory University (US)
- Oregon Health & Science University (US)
- University of California, San Francisco (US)
- University of Michigan (US)
- University Medical Center (US)
- British Heart Foundation (GB)
- Massachusetts General Hospital (US)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Lahey Medical Center (US)
- Meyer Children's Hospital (IT)
- Institute of Cardiology (PL)
- Cytokinetics (United States) (US)
- Complexo Hospitalario Universitario A Coruña (ES)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Instituto de Investigación Biomédica de A Coruña (ES)
- University College London (GB)
- University of Missouri–Kansas City (US)
- University of Glasgow (GB)
- University of Pennsylvania (US)
Publication Details
- Journal
- JACC Heart Failure
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1016/j.jchf.2025.03.008
- Citations
- 1
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Cytokinetics